Skip to main content

Table 1 Patient characteristics

From: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

 

CD

UC

Patients number (n = 112)

84

28

Males/females

39/45 (46%/54%)

11/17 (39%/60%)

Mean age at TDM (SD)

36 years (10.9)

35 years (11.2)

Mean duration of adalimumab therapy (SD)

157.8 weeks (101.7)

70.1 weeks (58.0)

Age at onset (<16y/17-40y/>40y)

13/64/7

-

Localisation of Crohn’s disease (ileal/colon/ileocolon/upper GI/ileocolon + upper GI)

13/16/47/2/5

-

Extension of colitis (proctitis/left sided/extensive)

-

0/19/9

Behaviour of CD (inflammatory/stricturing/penetrating/strict. + pen.)

29/18/27/10

-

Perianal disease in CD

42/84 (50%)

-

Previous surgery

43/84 (48.8%)

0/28 (0%)

Smoking (yes/no/previous)

44/24/16

19/2/7

Previous 5-ASA

69/84 (82.1%)

26/28 (93%)

Previous steroid

76/84 (90.5%)

28/28 (100%)

Previous/concomitant AZA

67/84 (80%)/42/84 (50%)

20/28 (71.4%)/2/28 (28.6%)

Previous anti-TNF

50/84 (60.2%)

23/28 (82%)

Previous IFX/ADM/both

38/5/7

22/1/0

  1. (CD Crohn’s disease, UC Ulcerative colitis, SD Standard deviation, TDM Therapeutic drug monitoring, GI Gastrointestinal, 5-ASA 5-aminosalycilate, AZA Azathioprine, anti-TNF Anti-tumor necrosis factor, IFX Infliximab, ADM Adalimumab)